Philosophy Capital Management LLC Makes New Investment in Arvinas, Inc. $ARVN

Key Points

• Philosophy Capital Management LLC has made a new investment of $6.99 million in Arvinas, acquiring 996,032 shares, representing approximately 0.5% of its investment portfolio.
• Several institutional investors, including Vanguard and Federated Hermes, have increased their stakes in Arvinas, with 95.19% of the company currently owned by institutional investors.
• Wall Street analysts have set a price target of around $19.76 for Arvinas, with ratings ranging from "Moderate Buy" to "Hold," reflecting varying outlooks on the company's performance.

Philosophy Capital Management LLC purchased a new position in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 996,032 shares of the company's stock, valued at approximately $6,992,000. Arvinas accounts for about 0.5% of Philosophy Capital Management LLC's investment portfolio, making the stock its 29th biggest holding. Philosophy Capital Management LLC owned 1.36% of Arvinas at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. GF Fund Management CO. LTD. acquired a new stake in Arvinas during the 4th quarter worth approximately $28,000. GAMMA Investing LLC raised its holdings in shares of Arvinas by 11,283.8% during the first quarter. GAMMA Investing LLC now owns 4,212 shares of the company's stock worth $300,000 after acquiring an additional 4,175 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in shares of Arvinas by 965.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company's stock worth $33,000 after acquiring an additional 4,219 shares during the period. CWM LLC raised its holdings in shares of Arvinas by 2,317.5% during the first quarter. CWM LLC now owns 7,615 shares of the company's stock worth $53,000 after acquiring an additional 7,300 shares during the period. Finally, Aigen Investment Management LP bought a new stake in Arvinas in the 1st quarter valued at $77,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Andrew Saik sold 5,700 shares of the company's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $7.61, for a total transaction of $43,377.00. Following the completion of the sale, the chief financial officer directly owned 164,401 shares in the company, valued at approximately $1,251,091.61. This represents a 3.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.73% of the stock is owned by company insiders.

Arvinas Stock Up 0.8%

Shares of ARVN stock traded up $0.06 on Tuesday, reaching $8.00. The stock had a trading volume of 1,206,339 shares, compared to its average volume of 1,435,460. Arvinas, Inc. has a 12 month low of $5.90 and a 12 month high of $29.61. The firm's 50-day moving average is $7.52 and its two-hundred day moving average is $8.27.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.03. The business had revenue of $22.40 million during the quarter, compared to the consensus estimate of $34.42 million. Arvinas had a negative return on equity of 12.01% and a negative net margin of 19.47%.The company's quarterly revenue was down 70.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.49) EPS. Sell-side analysts predict that Arvinas, Inc. will post -3.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ARVN shares. Leerink Partnrs downgraded Arvinas from a "strong-buy" rating to a "hold" rating in a research note on Sunday, June 1st. Leerink Partners reissued a "market perform" rating and issued a $9.00 target price (down previously from $10.00) on shares of Arvinas in a research report on Monday, June 2nd. Wells Fargo & Company reduced their price target on Arvinas from $19.00 to $16.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. Guggenheim lowered their price objective on shares of Arvinas from $16.00 to $15.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Finally, UBS Group cut their price objective on shares of Arvinas from $74.00 to $21.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Twelve research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, Arvinas currently has a consensus rating of "Moderate Buy" and a consensus price target of $19.76.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.